Monitoring institutional buy signals and regulatory milestones will remain essential for investors following the BMY stock forecast 2025 into mid-decade performance cycles. READ NEXT: 20 Best AI Stock To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap Bristol Myers posted net income of $2.5 billion, or $1.20 per share, for the first quarter. That compares with a net loss of $11.9 billion, or a loss of $5.89 per share, for the year-earlier period. Research desk summaries indicate that BMY stock forecast 2025 depends heavily on U.S. reimbursement stability and international growth, notably from Asia-Pacific oncology markets.
